These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38145305)

  • 1. New Indole-6-Carboxylic Acid Derivatives as Multi-Target Antiproliferative Agents: Synthesis, in Silico Studies, and Cytotoxicity Evaluation.
    Allawi MM; Mahmood AAR; Tahtamouni LH; AlSakhen MF; Kanaan SI; Saleh KM; Yasin SR
    Chem Biodivers; 2024 Feb; 21(2):e202301892. PubMed ID: 38145305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, docking study, and antitumor evaluation of benzamides and oxadiazole derivatives of 3-phenoxybenzoic acid as VEGFR-2 inhibitors.
    Heriz MH; Mahmood AAR; Yasin SR; Saleh KM; AlSakhen MF; Kanaan SI; Himsawi N; Saleh AM; Tahtamouni LH
    Drug Dev Res; 2024 May; 85(3):e22186. PubMed ID: 38643351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors.
    Mahmoud MA; Mohammed AF; Salem OIA; Almutairi TM; Bräse S; Youssif BGM
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2305856. PubMed ID: 38326989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel 1,3,4-oxadiazole derivatives of naproxen targeting EGFR: Synthesis, molecular docking studies, and cytotoxic evaluation.
    Alsaad HN; Al-Jasani BM; Mahmood AAR; Tahtamouni LH; Saleh KM; AlSakhen MF; Kanaan SI; Yasin SR
    Drug Dev Res; 2024 Aug; 85(5):e22231. PubMed ID: 38956926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new 5-(2,6-dichlorophenyl)-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-7-carboxylic acids as p38α MAPK inhibitors: Design, synthesis, antitumor evaluation, molecular docking and in silico studies.
    El-Wakil MH; El-Dershaby HA; Ghazallah RA; El-Yazbi AF; Abd El-Razik HA; Soliman FSG
    Bioorg Chem; 2024 Apr; 145():107226. PubMed ID: 38377818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel 5-bromoindole-2-carboxylic Acid Derivatives as EGFR Inhibitors: Synthesis, Docking Study, and Structure Activity Relationship.
    Hassan OM; Kubba A; Tahtamouni LH
    Anticancer Agents Med Chem; 2023; 23(11):1336-1348. PubMed ID: 36847231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
    Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
    Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Carbothioamide and Carboxamide Derivatives of 3-Phenoxybenzoic Acid as Potent VEGFR-2 Inhibitors: Synthesis, Molecular Docking, and Cytotoxicity Assessment.
    Heriz MH; Mahmood AAR; Tahtamouni LH; AlSakhen MF; Kanaan SI; Saleh KM; Yasin SR
    Curr Cancer Drug Targets; 2024 May; ():. PubMed ID: 38747227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semicarbazides Carrying Indole Core: Synthesis, Cytotoxicity Evaluation against Human Breast Cancer Cell Lines, and Molecular Modeling Studies.
    Çelik B; Buran Uğur S; Baran M; Gündüz MG; Keskin S; Önder GÖ; Bitgen N; Kaya S; Doğan ŞD
    Chem Biodivers; 2023 Aug; 20(8):e202300609. PubMed ID: 37423889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of New Quinazoline Derivatives as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-proliferative Studies.
    Dhawale SA; Dabhade PS; Mokale SN
    Anticancer Agents Med Chem; 2023; 23(18):2042-2055. PubMed ID: 37455449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the Promising Anticancer Activity of Cetuximab and Fenbendazole Combination as Dual CBS and VEGFR-2 Inhibitors and Endowed with Apoptotic Potential.
    Eid NM; Al-Karmalawy AA; Eldebss TMA; Elhakim HKA
    Chem Biodivers; 2024 Apr; 21(4):e202302081. PubMed ID: 38318954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity, anti-angiogenic, anti-tumor and molecular docking studies on phytochemicals isolated from Polygonum hydropiper L.
    Mahnashi MH; Alqahtani YS; Alyami BA; Alqarni AO; Ullah F; Wadood A; Sadiq A; Shareef A; Ayaz M
    BMC Complement Med Ther; 2021 Sep; 21(1):239. PubMed ID: 34560864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
    Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
    Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and antitumor screening of new thiazole, thiazolopyrimidine, and thiazolotriazine derivatives as potent inhibitors of VEGFR-2.
    Abd Elhameed AA; Ali AR; Ghabbour HA; Bayomi SM; El-Gohary NS
    Drug Dev Res; 2023 Dec; 84(8):1664-1698. PubMed ID: 37661648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Novel Indazolyl-Acyl Hydrazones as Antioxidant and Anticancer Agents that Target VEGFR-2 in Human Breast Cancer Cells.
    Parameshwaraiah SM; Shivakumar R; Xi Z; Siddappa TP; Ravish A; Mohan A; Poonacha LK; Uppar PM; Basappa S; Dukanya D; Gaonkar SL; Kemparaju K; Lobie PE; Pandey V; Basappa B
    Chem Biodivers; 2024 Mar; 21(3):e202301950. PubMed ID: 38258537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting EGFR and VEGFR-2 Kinases With Nanoparticles: A Computational Approach for Cancer Therapy Advancement.
    Khater I; Nassar A
    Cancer Invest; 2024 Feb; 42(2):176-185. PubMed ID: 38486424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.